General Information
Version
2.0
Revision date
2017-11-27
Product name
LJPC-501
Product name
LJPC-501
Identification on the label/Trade name
Not applicable
Product Synonyms
LJPC-501 (angiotensin II) Injection
Chemical name
Mixture
CAS No.
68521-88-0
1.2.1 Relevant identified uses
Bulk formulated pharmaceutical mixture/Formulated pharmaceutical product/ of the substance or mixture packaged for use in clinical trials;under investigation for the treatment of mixture and uses catecholamine-resistant hypotension, and hepatorenal syndrome
Emergency telephone
+1 (800) 424-9300, +1 (703) 527-3887
Icons in SDS
Company Information
company name
La Jolla Pharmaceutical Co
e-mail address of the competent person responsible for the Safety Data Sheet
SDScoordinator@ljpc.com
GHS Information
Signal word
None required
Section 2
SECTION 2: Hazards identification
2.1 Classification of the substance or mixture
substance or mixture Globally Harmonized Not classified System [GHS]
2.2 Label elements
SECTION 2 - HAZARDS IDENTIFICATION …continued
Hazard statements
None required None required
Signal word
None required
Precautionary statements
None required
2.3 Other hazards
Angiotensin II is a hormone that interacts with the central nervous system to regulate renal sympathetic nerve activity, renal function, and (therefore) blood pressure. It plays a critical role in the regulation of water and sodium homeostasis. In clinical trials, the most commonly reported adverse effects associated with use of angiotensin II include increased blood pressure, increased urine output, transient headache, palpitations, sodium retention accompanied by weight gain, and excretion of excessive amounts of sodium in the urine. Based on its pharmacological effect (i.e., vasoconstriction), the potential for angiotensin II acetate to adversely affect fertility and/or fetal development cannot be ruled out in the absence of definitive data. Note This mixture does not meet criteria for classification under GHS as implemented
